loading...| Preferred Name | Suramin | |
| Synonyms |
SURAMIN Suramin suramin |
|
| Definitions |
A polysulphonated naphthylurea with potential antineoplastic activity. Suramin blocks the binding of various growth factors, including insulin-like growth factor I (IGF-I), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and tumor growth factor-beta (TGF-beta), to their receptors, thereby inhibiting endothelial cell proliferation and migration. This agent also inhibits vascular endothelial growth factor (VEGF)- and basic fibroblast growth factor (bFGF)-induced angiogenesis; retroviral reverse transcriptase; uncoupling of G-proteins from receptors; topoisomerases; cellular folate transport; and steroidogenesis. (NCI04) |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C853 |
|
| Accepted_Therapeutic_Use_For |
Trypanosomiasis; hormone-refractory prostate cancer |
|
| ALT_DEFINITION |
A drug that is used to treat infections caused by parasites. It is also being studied in the treatment of cancer. It belongs to the families of drugs called antiprotozoals and anthelmintics. |
|
| CAS_Registry |
145-63-1 |
|
| CHEBI_ID |
CHEBI:45906 |
|
| Chemical_Formula |
C51H40N6O23S6 |
|
| code |
C853 |
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
| Contributing_Source |
CTRP FDA GDC HemOnc |
|
| DEFINITION |
A polysulphonated naphthylurea with potential antineoplastic activity. Suramin blocks the binding of various growth factors, including insulin-like growth factor I (IGF-I), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and tumor growth factor-beta (TGF-beta), to their receptors, thereby inhibiting endothelial cell proliferation and migration. This agent also inhibits vascular endothelial growth factor (VEGF)- and basic fibroblast growth factor (bFGF)-induced angiogenesis; retroviral reverse transcriptase; uncoupling of G-proteins from receptors; topoisomerases; cellular folate transport; and steroidogenesis. (NCI04) |
|
| Display_Name |
Suramin |
|
| FDA_UNII_Code |
6032D45BEM |
|
| FULL_SYN |
SURAMIN Suramin suramin |
|
| Has_Salt_Form | ||
| Has_Target |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C41029 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17322 |
|
| Is_Value_For_GDC_Property | ||
| label |
Suramin |
|
| Legacy Concept Name |
Suramin |
|
| Maps_To |
Suramin |
|
| NCI_Drug_Dictionary_ID |
40052 |
|
| PDQ_Closed_Trial_Search_ID |
40052 |
|
| PDQ_Open_Trial_Search_ID |
40052 |
|
| Preferred_Name |
Suramin |
|
| prefixIRI |
Thesaurus:C853 |
|
| Semantic_Type |
Organic Chemical Pharmacologic Substance |
|
| UMLS_CUI |
C0038880 |
|
| subClassOf |